CRISM Therapeutics Corporation (AIM:CRTX)
London
· Delayed Price · Currency is GBP · Price in GBX 13.00
+0.50 (4.00%)
Mar 9, 2026, 3:36 PM GMT
CRISM Therapeutics Income Statement
Financials in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | - | - | 0.05 | - | - | - | Upgrade
|
| Other Revenue | 0.03 | 0.03 | - | - | - | - | Upgrade
|
| Revenue | 0.03 | 0.03 | 0.05 | - | - | - | Upgrade
|
| Revenue Growth (YoY) | -44.44% | -44.44% | - | - | - | - | Upgrade
|
| Cost of Revenue | 0.01 | 0 | 0.03 | - | - | - | Upgrade
|
| Gross Profit | 0.02 | 0.02 | 0.01 | - | - | - | Upgrade
|
| Selling, General & Admin | 1.32 | 0.72 | 0.14 | 1.85 | 1.32 | 2.26 | Upgrade
|
| Research & Development | 0.17 | 0.17 | 0.03 | - | - | - | Upgrade
|
| Operating Expenses | 1.51 | 0.9 | 0.18 | 1.85 | 1.32 | 2.26 | Upgrade
|
| Operating Income | -1.49 | -0.88 | -0.17 | -1.85 | -1.32 | -2.26 | Upgrade
|
| Interest Expense | - | -0.01 | -0.03 | - | - | -0.01 | Upgrade
|
| Interest & Investment Income | - | - | - | - | - | 0.15 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | - | -0 | 0 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | - | - | - | -0.07 | Upgrade
|
| EBT Excluding Unusual Items | -1.49 | -0.89 | -0.2 | -1.85 | -1.32 | -2.18 | Upgrade
|
| Asset Writedown | - | - | - | - | - | 0.31 | Upgrade
|
| Other Unusual Items | - | 0.3 | - | -0.32 | - | -0.08 | Upgrade
|
| Pretax Income | -1.49 | -0.59 | -0.2 | -2.16 | -1.32 | -1.95 | Upgrade
|
| Income Tax Expense | - | - | -0.01 | - | - | - | Upgrade
|
| Earnings From Continuing Operations | -1.49 | -0.59 | -0.2 | -2.16 | -1.32 | -1.95 | Upgrade
|
| Earnings From Discontinued Operations | -0.04 | -0.01 | - | -0.34 | 0.43 | - | Upgrade
|
| Net Income | -1.52 | -0.61 | -0.2 | -2.5 | -0.89 | -1.95 | Upgrade
|
| Net Income to Common | -1.52 | -0.61 | -0.2 | -2.5 | -0.89 | -1.95 | Upgrade
|
| Shares Outstanding (Basic) | 45 | 32 | 0 | 9 | 9 | 7 | Upgrade
|
| Shares Outstanding (Diluted) | 45 | 32 | 0 | 9 | 9 | 7 | Upgrade
|
| Shares Change (YoY) | 39.18% | 201033.86% | -99.82% | 0.85% | 28.82% | 45.57% | Upgrade
|
| EPS (Basic) | -0.03 | -0.02 | -12.25 | -0.29 | -0.10 | -0.29 | Upgrade
|
| EPS (Diluted) | -0.03 | -0.02 | -12.25 | -0.29 | -0.10 | -0.29 | Upgrade
|
| Free Cash Flow | -1.33 | -0.93 | -0.1 | -2.92 | -1.67 | -2.02 | Upgrade
|
| Free Cash Flow Per Share | -0.03 | -0.03 | -6.13 | -0.34 | -0.19 | -0.30 | Upgrade
|
| Gross Margin | 72.00% | 84.00% | 28.89% | - | - | - | Upgrade
|
| Operating Margin | -5952.00% | -3520.00% | -377.78% | - | - | - | Upgrade
|
| Profit Margin | -6096.00% | -2428.00% | -435.56% | - | - | - | Upgrade
|
| Free Cash Flow Margin | -5336.00% | -3732.00% | -217.78% | - | - | - | Upgrade
|
| EBITDA | -1.47 | -0.86 | -0.15 | -1.62 | -1.12 | -2.26 | Upgrade
|
| D&A For EBITDA | 0.02 | 0.02 | 0.02 | 0.23 | 0.2 | 0 | Upgrade
|
| EBIT | -1.49 | -0.88 | -0.17 | -1.85 | -1.32 | -2.26 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.